Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company’s drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. The company is headquartered in Hampton, New Jersey.
Financial Outlook | Analysts set price targets ranging from $67 to $80, reflecting optimism about Celldex's $673 million cash position and potential for multi-indication expansion |
Market Dynamics | Uncover the substantial market opportunity for barzolvolimab, with analysts projecting peak sales of $1 billion in CSU alone, amid growing competition |
Clinical Milestones | Delve into Celldex's ongoing clinical trials, including the encouraging 76-week data for CSU and the anticipated Phase 2 EvolvE trial results for EoE in 2025 |
Barzolvolimab's Promise | Explore barzolvolimab's potential as a game-changing treatment for chronic spontaneous urticaria and eosinophilic esophagitis, addressing significant unmet medical needs |
Metrics to compare | CLDX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCLDXPeersSector | |
---|---|---|---|---|
P/E Ratio | −8.3x | −0.1x | −0.5x | |
PEG Ratio | −1.93 | 0.02 | 0.00 | |
Price / Book | 2.1x | 1.8x | 2.6x | |
Price / LTM Sales | 197.3x | 9.5x | 3.1x | |
Upside (Analyst Target) | 158.2% | 145.1% | 45.7% | |
Fair Value Upside | Unlock | 17.1% | 5.7% | Unlock |